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Summary. The effects of monoclonal antibody (MAb) C179 recognizing a con-
formational epitope in the middle of the hemagglutinine (HA) stem region were
examined in a mouse model in the experiments of prevention and treatment of
lethal bronchopneumonia caused by influenza A virus of H5 subtype. To model
the lethal infection, avian nonpathogenic strain A/mallard duck/Pennsylvania/
10218/84 (H5N2) was adapted to mice. This resulted in highly pathogenic pneu-
movirulent mouse-adapted (MA) variant, which was characterized. Three amino
acid changes were found in the HA1 subunit of HA of MA virus. One of these
was located inside the region of the conformational epitope recognized by MAb
C179. However, this substitution was not significant for the recognition of HA
and virus neutralization by MAb C179 in vitro and in vivo. Intraperitoneal ad-
ministration of two different concentrations of MAb C179 one day before or
two days after the virus challenge significantly decreased mortality rate. These
results suggest that MAb C179 is efficient not only in the prevention and treat-
ment of H1 and H2 influenza virus bronchopneumonia, as was reported previ-
ously, but also of H5-induced bronchopneumonia as well, and demonstrate in
vivo the existence of a common neutralizing epitope in the HAs of these three
subtypes.
*
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Protective immunity toward influenza virus infection is mainly based on the pres-
ence of neutralizing antibodies. The viral envelope glycoprotein hemagglutinin
(HA) is the major virus neutralization-inducing moiety of influenza virus [9].
The antibody binding sites of influenza A virus HA are located predominantly in
the HA1 globular domain [20]. The amino acid sequences of these regions are
extremely variable not only among different subtypes of HA, but also within a
single subtype. On the other hand, some conserved and cross-reactive antigenic
determinants were observed in the HA2 subunit of the HA [4, 6, 12, 19]. It may be
supposed that highly conserved antigenic sites on different HA molecules induce
neutralizing antibodies to different HA subtypes. Furthermore, Okuno et al. [10,
11] find and described a conformational antigenic epitope in the middle of the stem
region of HA of H2 subtype consisting of two regions (aa 318–322 of the HA1
– A region, and aa 47–58 of the HA2 – B region), which was conserved among
HAs of all studied viruses belonging of H1 and H2 subtypes. Monoclonal anti-
body C179 recognizing this epitope possessed unique broad cross-neutralizing
activity among H1 and H2 influenza viruses [10], and was effective for prevention
and treatment of experimental bronchopneumonia caused by viruses of these sub-
types in mice [8, 11]. Recently, we described the existence of this conformational
epitope in HA of H5 and H6 subtypes too [17]. After the outbreak caused by H5
influenza virus in Hong Kong in 1997, which clearly demonstrate the possibility
of insertion of new influenza A virus subtypes into human population [1, 3, 18],
such conserved cross-neutralizing determinants in HA may acquire significance
as potential target for urgent prevention and treatment measures.
In the present study we have examined the interaction of MAb C179 with H5
influenza virus in animal model. The main aims of this study were to demonstrate
in the experiments in vivo the existence of conformational neutralizing epitope
in HA of H5 subtype, and to determine the efficacy of MAb C179 for prevention
and treatment of experimental H5 influenza virus-induced bronchopneumonia in
mice.
Avian non-pathogenic strain A/mallard duck/Pennsylvania/10218/84 (H5N2)
(mld/PA/84) was kindly provided by Dr. R. G. Webster. Highly pathogenic pneu-
movirulent mouse-adapted (MA) variant of this strain (mld/PA/84-MA) was ob-
tained by 23 serial lung-to-lung passages and isolated by one passage in embry-
onated chicken eggs [7]. MA variant caused bronchopneumonia in mice with
high mortality rate: log10 of LD50 for mld/PA/84-MA, determined by the method
described previously [14], was equal to 6.0/0.1 ml. Original strain mld/PA/84 did
not cause illness and mortality in infected mice. The HA gene of mld/PA/84-MA
were sequenced and translated as described previously [17] (GenBank accession
number AF 100179). Comparison of amino acid sequences of HA between orig-
inal strain mld/PA/84 and MA variant revealed three amino acids substitutions:
S203→F, E273→G and L273→P (H3 numbering system [21]). One of them at po-
sition 320 is located in the A region (aa 318–322) of the conformational epitope
recognized by MAb C179.
MAb C179 was generously supplied by Takara Shuzo Co. Ltd., Biotechnol-
ogy Research Laboratories, Japan as standard preparation of purified ascitic fluid
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Fig. 1. Radioimmunoprecipitation assay of mld/PA/84-MA with Mab C179. Virus-infected
MDCK cells were labeled with [35S] methionine (50mCi/ml) at 4.5 h post infection for 1 h.
After that the cells were scraped off and suspended in STE buffer (pH 7.4). The cell suspension
was centrifuged and disrupted in RIPA buffer. One third of cell lysates were subjected directly
to polyacrylamide gel electrophoresis (PAGE) and the remainder was used in RIPA. PAGE
and RIPA were carried out as described previously [17]. 1 Mock-infected cells control; 2, 4, 6
lysates of cells infected with black dk/NJ/78-MA (H2N3) (positive control), mld/PA/84-MA
(H2N2) and FPV/Weybr./27 (H7N7) (negative control); 3, 5, 7 HAs of black d/NJ/78-MA,
mld/PA/84-MA, and FPV/Weybr./27 respectively precipitated with MAb C179
with MAb concentration 10 mg/ml. Before the studies in animals mld/PA/84-MA
virus was tested with MAb C179 in radioimmunoprecipitation assay (RIPA) and
cytopathic effect (CPE) neutralization test in MDCK cells, which were carried
out according to the methods described previously [17]. MA variant of avian H2
strain A/black duck/New Jersey/1580/78-MA (H2N3) (black dk/NJ/78-MA) re-
acting with MAb C179 [7, 8] was chosen as positive control in these experiments.
A/FPV/Weybrige/27 (H7N7) (FPV/Weybr./27) phylogenetically distant from H2
and H5 viruses and not reacting with MAb C179 [17] was used as negative con-
trol. The results of RIPA are shown in Fig. 1. MAb C179 precipitated the H5 HA
as efficiently as the H2 HA and failed to react with H7 subtype strain, confirming
the specificity of the precipitation. The results of RIPA correlate with CPE neu-
tralization test (Table 1). MAb C179 in different concentrations neutralized the
CPE caused by H5 and H2 strains. As expected, the MAb did not influence the
infectivity of H7 virus, confirming the specificity of virus neutralization. These
results show that MAb C179 recognizes HA and neutralizes the infectivity of
mld/PA/84-MA in experiments in vitro. These data allowed us to perform further
studies of MAb C179 in mice.
Four-week-old unbred albino mice were inoculated intraperitonealy with
100ml of undiluted ascitic fluid (1000mg of C179 per mouse) or with 100ml of
appropriate dilution of MAb in sterile 0.9% NaCl solution 24 h before
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Table 1. Infectivity neutralization test of mld/PA/84-MA with MAb C179
Concentration of MAb C179 (mg/ml)
Viruses 100.0 10.0 1.0 0.5
black dk/NJ/78-MA (H2N3) ≥1.875 1.5 0.5 ND
mld/PA/84-MA (H5N2) ≥2.125 ≥2.125 1.125 0.5
FPV/Weybr./27 (H7N7) 0 0 0 ND
Different concentrations of MAb C179 were mixed with 100 TCID50 of
viruses and incubated at 37 ◦C for 45 min. Subsequently, the virus-MAb mixtures
were serially 10-fold diluted in DMEM supplemented with 0.2% bovine serum
albumin and 1mg/ml trypsin, and added to a confluent monolayer of MDCK cells
in 96-well flat bottom microtiter plates. After incubation at 37 ◦C in 5% CO2
for 72 h, the cells were checked for CPE and the TCID50 titers were determined.
The results presented as differences between log10 values of TCID50 obtained
with the concentration of MAb indicated and with the control. ND Not done
(prevention) or 48 h after (treatment) the virus challenge. Control groups received
intraperitonealy 100ml of sterile 0.9% NaCl solution alone. To confirm specific
action of MAb C179 additional control groups of mice were inoculated intraperi-
tonealy with 100ml of mouse ascitic fluid without MAbs 24 h before or 48 h
after the virus challenge. Ether anaesthetized albino mice were infected by in-
tranasal inoculation with 50ml of PBS-diluted allantoic fluid contained 10LD50
of mld/PA/84-MA. Effects of MAb C179 for prevention and treatment of lethal
bronchopneumonia were estimated on the basis of differences in survival rates
calculated for groups of animals having received different concentrations of MAb
and control groups after an observation period of 15 days.
The survival rates in mice, which received MAb C179 a day before the chal-
lenge with mld/PA/84-MA, are shown in Fig. 2A. A total of 70 mice were ran-
domly divided into four groups: three of 20 mice and one of 10. Two experimental
groups received 1000 and 100mg of C179 per mouse, respectively. The control
groups received 0.9% NaCl solution (20 animals) or mouse ascitic fluid (10 ani-
mals). The survival rate in the group of mice that received 1000mg of MAb was
100%. In the group that received 100mg of MAb C179 survival rate was 90%.
Mortality in the group treated with 0,9% NaCl solution as well as with mouse
ascitic fluid (data not shown) was equal 100% at the thirteenth day after infec-
tion. The statistical evaluation of the results presented in Fig. 2A by sign test, an
unparametritical statistical test [5], revealed that the differences in the survival
rates between the groups of mice injected with MAb (1000 or 100mg) and the
control groups was significant at 0.01 level. These results indicate that MAb C179
efficiently protected mice from lethal infection with mld/PA/84-MA.
The therapeutical effect of MAb on the infection of mice caused by H5N2-
MA virus is shown in Fig. 2B. Three groups of 20 mice were injected with
1000 or 100mg of MAb C179 or with 0.9% NaCl solution (control) two days
after the virus infection. Additional control groups of 10 animals received mouse
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Fig. 2. Survival rates in mice received MAb C179 24 h before (A) or 48 h after (B)
the challenge with mld/PA84-MA (H5N2). Four-week-old albino mice were inoculated
intraperitonealy with 1000.0 (-d-) or 100.0 (-m-) mg of MAb per mouse. Control groups
(-u-) received sterile 0.9% NaCl solution
ascitic fluid without MAbs at the same time (data not shown). Survival rates in
mice received 1000 and 100mg of C179 were equal 80 and 75% respectively.
In both control groups 100% mortality rate was observed. The differences in the
survival rates among the groups of mice that received 1000 and 100mg of MAb
and the control groups were significant at 0.01 level. These data show that C179
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is effective for treatment of H5-induced pneumonia. The administration of MAb
C179 significantly decreases mortality in animals even when infection is initiated.
The mechanism underlying the action of MAb C179 is known in general [10,
11]. The binding of this MAb with the conformational epitope in the middle of
the HA stem region, most likely, prevents the low pH-induced conformational
changes in HA molecule and inhibits the fusion activity of HA. In vivo experi-
ments for prevention of lethal pneumonia caused by H1 influenza virus in mice
revealed that MAb C179 does not prevent the initiation of viral infection, however
it efficiently inhibits the spread of infection in mouse lungs [11]. These results
correlate with the location of haemorrhagic lesions in the lungs of infected mice
observed in our previous [8] and present studies. The lesions in the lungs of mice
that received 1000 or 100mg of MAb C179 a day before the virus challenge were
localized in small areas only at the sites adjacent to the bronchi, while in the
infected control group those were spread all over the lungs (data not shown).
The amino acid sequences of A and B regions forming conformational epitope
in HA of H1 and H2 viruses studied previously in mice model with MAb C179
[8, 11], and H5 strains are presented in Table 2. These parts of HA molecule are
highly conserved among the presented subtypes. MAb C179 was obtained against
HA of human H2N2 strain, and it was shown that amino acid sequences of A and
B regions are identical among human H1 and H2 viruses [10]. The MA-variant of
avian strain black dk/NJ/78-MA (H2N3) possesses one amino acid replacement
Table 2. Comparison of amino acid sequences of A and B regions
forming the conformational epitope in the HA stem region among
H1, H2 and H5 strains
Amino acid positions
HA1 HA2
Viruses A region B region
318 322 47 58
FM/1/47 (H1N1) TGLRN GITNKVNSVIEK
USSR/90/77-MA (H1N1) TGLRN GITNKVNSVIEK
black dk/NJ/78-MA (H2N3) IGLRN GITNKVNSVIEK
mald/PA/84-MA (H5N2) TGPRN GITNKVNSIIDK
mald/PA/84 (H5N2) TGLRN GITNKVNSIIDK
tern/SA/61 (H5N3) TGLRN GITNKVNSIIDK
Hong Kong/97 (H5N1) TGLRN GVTNKVNSIINK
The HA gene of mld/PA/84-MA was sequenced and submitted to
GenBank under accession number AF100179. Published sequences:
A/FM/1/47 (FM/1/47) [16], A/USSR/90/77 [2] (sequences of these
regions in HA of USSR/90/77-MA is identical [22]), A/mallard
duck/Pennsylvania/10218/84 (parental, avirulent for mice strain)
[17], A/tern/South Africa/61 [13], and A/Hong Kong/156/97 [1].
Sequence of HA of A/black duck/ NJ/1580/78-MA is a personal
communication of E. A. Govorkova and N. V. Makarova
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in A region (T318→I) deffering the MA strain from the parental virus and other
H2 viruses. This amino acid change in HA of avian H2-MA virus is a result of
adaptation to mice. It had no effect upon the reaction of MAb C179 with black
dk/NJ/78-MA in vitro (Fig. 1; Table 1) and in vivo [8]. In the case of H5 virus
mld/PA/84-MA there are three amino acid differences (one in A region and two
in B region) which differ the epitope from that in H1 and H2 viruses (Table 2).
Two amino acid replacements in B region (V55→I and E57→D) are typical for
most of avian H5 strains (Table 2) and do not influence the recognition of H5 HA
by MAb C179 [17]. The HA of avian-like H5 viruses isolated from humans in
1997 in Hong Kong possess two substitutions in B region (I48→V and D57→N)
which differ this part of molecule from that in other avian H5 strains (Table 2).
The amino acid substitution in A region at residue 320 (L→P) is characteristic of
H5 HA of MA strain as a result of adaptation to mice. The A region in the HA of
the original virus mld/PA/84 as well as in other H5 viruses is identical to that in
H1 and H2 strains (Table 2). Two other substitutions (S203→F, E273→G) in HA
of H5 MA virus also do not influence the interaction of MAb with the epitope.
These results indicate that conserved conformational epitope in the middle of HA
stem region of H5 and avian H2 strains may be changed in the course of virus
adaptation to new host. It is possible to assume that these changes in HA during
adaptation of these avian strains to mice are result of selection by the organism of
new host and lead to the acquisition of virulence. These changes have no effect
on the recognition of HA and viral neutralization by MAb C179.
The results of the present study confirm our data that HAs of H5, H1 and
H2 influenza A viruses possess common neutralizing epitope [17]. MAb C179
directed to this epitope is efficient in the prevention and treatment of lethal in-
fluenza virus bronchopneumonia caused by H5 virus in mice as well as the one
caused by H1 and H2 viruses [8, 11]. Present results together with previously
reported data about cross-neutralizing epitope and MAb C179 [8, 10, 11, 15, 17]
make it possible to suppose that this highly conserved determinant in HA might
be unique potential target for prevention and treatment of influenza A virus infec-
tion caused at least by H1, H2 and H5 strains. A search of such highly conserved
antigenic and cross-neutralizing epitops among phylogeneticaly closed subtypes
of influenza A viruses might be useful approach for development of vaccines and
antiviral drugs of broad activity.
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